Therapeutic Classification: antihypertensives
Pharmacologic Classification: ace inhibitors
 
Absorption: 13% bioavailability as moexiprilat following oral administration (↓ by food).
Distribution: Crosses the placenta.
Protein Binding: Moexipril: 90%; Moexiprilat: 5070%.
Metabolism/Excretion: Converted by liver and GI mucosa to moexiprilat, the active metabolite; 13% excreted in urine, 53% excreted in feces.
Half-Life: Moexipril: 1 hr; Moexiprilat: 29 hr (↑ in renal impairment).
 
(antihypertensive effect with chronic dosing)
| ROUTE | ONSET | PEAK | DURATION | 
|---|
| PO | within 1 hr | 4 wk | up to 24 hr | 
 
Contraindicated in: 
- Hypersensitivity;
 - History of angioedema with previous use of ACE inhibitors;
 - Concurrent use with aliskiren in patients with diabetes or moderate to severe renal impairment (CCr <60 mL/min);
 - OB: Pregnancy;
 - Lactation: Lactation.
 
Use Cautiously in: 
- Renal impairment, hypovolemia, hyponatremia, and concurrent diuretic therapy;
 - Black patients (monotherapy for hypertension less effective, may require additional therapy; higher risk of angioedema);
 - Surgery/anesthesia (hypotension may be exaggerated);
 - Rep: Women of reproductive potential;
 - Geri: Initial dose ↓ recommended in older adults;
 - Pedi: Safety not established in children.
 
Exercise Extreme Caution in: 
- Family history of angioedema.